NCT04968184: An ongoing trial by KBP Biosciences
This trial is completed, but has been granted a delay in reporting its results.
It must report results 1 year, 1 month from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04968184 |
|---|---|
| Title | A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of KBP-5074 Mineralocorticoid Receptor Antagonist in Subjects With Uncontrolled Hypertension and Moderate or Severe (Stage 3b/4) CKD |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 5, 2021 |
| Completion date | Jan. 30, 2024 |
| Required reporting date | Jan. 30, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |